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ABSTRACT
Multiple myeloma (MM) is an incurable malignancy characterized by the
uncontrolled proliferation of long-lived plasma cells (PCs) in the bone marrow
(BM), which constitute at least 10% of BM cellularity. Normally, long-lived plasma
cells make up less than 1% of BM cells. Plasma cells become neoplastic when a
clonal PC population produces a monoclonal immunoglobulin protein. A diagnosis
of monoclonal gammopathy of undetermined significance (MGUS) is made when
there is an increase in monoclonal PCs within the BM, but less than 10%, and the
patient does not present with end-organ damage, which is associated with active
MM. Though not considered pathological at this stage, individuals with MGUS are
at an increased risk for developing MM. There are several challenging aspects in
treating MM including the high clonal heterogeneity of MM cells and its clinical
repercussions, thus making the malignancy difficult to treat. Further heterogeneity
is found in regard to disease onset, disease progression, therapeutic resistance,
and subsequent patient relapse.
The purpose of this project is to investigate the microniche of PCs as they
transition from premalignant to malignant myeloma cells in order to provide
valuable insight which can be exploited to test current and novel therapeutic
treatments. This project has demonstrated changes in the expression of fibronectin
and morphological differences in plasma cells within core biopsies, which may
support disease progression. Additionally, the purpose of this project is also to
v

generate a long-term 3D in vitro culture models of MM using a high-throughput
hydrogel platform. By using BM aspirates from MGUS and MM patients, results
demonstrated that this 3D culturing system is capable of reproducing key features
on long-lived PCs. Furthermore, these BM cultures maintained their abnormal
phenotypes for at least five days of culture. This extended timeframe allows for
better characterization of the mechanisms of action of current therapies and testing
of emerging treatments for this incurable disease.
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CHAPTER 1
INTRODUCTION
Multiple myeloma (MM) is an incurable hematological cancer caused by the
uncontrolled proliferation and expansion of plasma cells (PCs) within the bone
marrow (BM). This second most common hematologic malignancy is associated
with progressive immune dysregulation characterized by decreased antigenpresenting and effector cell function, loss of myeloma-reactive T lymphocyte
populations, and a BM microenvironment that promotes immune privilege. In 2019,
it is estimated that there will be 32,110 new cases of MM with approximately 12,960
deaths.1 The exact cause of MM is unknown and no avoidable risk factors have
been found. MM is more common in individuals over age 65. Furthermore, men
are slightly more likely to develop MM and individuals of African American descent
are twice as likely to develop the disease.1,2 Additionally, individuals with other PC
diseases, such as monoclonal gammopathy of undetermined significance (MGUS)
or a single tumor of PCs, are at a higher risk of developing MM. Once diagnosed,
a limited number of treatment options are available for patients, though MM can
be controlled in most patients, sometimes for many years. Without treatment, the
median survival rate is typically less than seven months, but treatment extends
survival to four to five years, with a five-year survival rate of 49%. Despite novel
therapeutic advancements, MM still remains an incurable neoplasia due to intrinsic
or acquired resistance to therapy.3
1

1.1 Plasma Cell Development
Plasma cells are terminally differentiated, non-dividing effector cells of the
B lymphocyte lineage. These cells are devoted to synthesizing and secreting
immunoglobulins (Igs), leading to a range of specificity of both lambda and kappa
light chains.4,5 To respond to microbial pathogens with specificity and rapidity, B
lymphocytes are regulated by their development in the BM and subsequent
activation in the periphery. PCs are maintained for extended periods allowing for
potential life-long immunity to pathogens, which constitutes a crucial component
of humoral immune memory.6 Though PCs are recognized as the basis of humoral
immunity, the complexities of PC development have made it apparent that not all
PCs are the same. They differ in lifespan, localization, and the expression of cell
surface markers and transcription factors associated with PC fate and
immunoglobulin secretion.7,8
PCs can become neoplastic when a clonal PC population produces a
monoclonal immunoglobulin protein, such as all IgG kappa or IgG lambda, and this
abnormal paraprotein can be detected in the blood and urine. In general, when
plasma cells become malignant and proliferate uncontrollably, this is diagnosed as
MM.

1.2 Characterization of Multiple Myeloma
Cancerous PCs, constituting ≥10% monoclonal PCs, can cause end-organ
damage including calcium (elevated), renal insufficiency, anemia, and bone
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lesions (C.R.A.B), thereby meeting criteria for active MM.9–11 The usual balance
between bone resorption and new bone formation is lost in MM, resulting in bone
destruction. Osteoclasts are increasingly prominent in the BM microenvironment
because of their activation by various cytokines and signaling pathways. The
excessive resorption by osteoclasts overpowers the protective effects of
osteoblasts, resulting in a cycle that ongoingly releases calcium in the blood
leading to hypercalcemia.12–14 Hypercalcemia can cause a variety of symptoms for
patients including excessive thirst, nausea, constipation, loss of appetite, and
confusion.
Renal failure in MM patients is most commonly due to the excessive
production of immunoglobulins by the myeloma cells. Depending on the size of
these abnormal paraproteins, they may be excreted through the kidneys, which
can cause damage. Additionally, hypercalcemia further contributes to renal failure
in patients.15
Anemia is present in 73% of patients at the presentation of the disease and
in 97% of patients during the course of the disease. This is caused by the
replacement of normal BM being infiltrated by malignant myeloma cells, leading to
the inhibition of normal red blood cell production.9
In the majority of myeloma patients, hypercalcemia can also cause bone
lesions and bone pain. Bone destruction develops adjacent to myeloma cells, yet
not in areas of normal BM.13 When more than 30% of the bone has been destroyed,
X-rays show a thinning of the bone (osteoporosis) or lytic lesions and these
weakened areas of bone are more likely to facture. Most patients experience bone
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pain, especially in the middle and/or lower back, rib cage, hips, or spine. Bone
fractures and spinal cord compression are the most common.11 This pain may be
mild or severe depending on the extent of the myeloma, the speed with which it
has developed, and whether a fracture or nerve compression has occurred.
There are other neoplastic plasma cell disorders that have abnormal PCs,
but do not meet the criteria to be classified as active MM. Monoclonal gammopathy
of undetermined significance (MGUS) is a precancerous condition and the most
common hematological malignancy capable of producing monoclonal plasma
cells.16,17 MGUS resembles MM, but the levels of antibodies are lower, the number
of PCs in the BM is lower (less than 10%), and patients do not present with endorgan damage.14,18 MGUS patients rarely have symptoms or major problems,
however these patients can progress to MM at an average rate of ~1% per
year.17,19,20 As a result, most patients never develop a PC malignancy and because
of this MGUS has gained a relatively benign reputation. Unfortunately, this is not
accurate as recently it has been recognized that nearly all cases of MM are
preceded by a period of MGUS.19

1.3 Bone Marrow Microenvironment
The

BM

microenvironment

consists

of

cellular

and

non-cellular

compartments.12,21–24 The cellular compartment can be subdivided into
hematopoietic cell types including myeloid cells, T lymphocytes, B lymphocytes,
natural killer cells, and osteoclasts, while non-hematopoietic cells include bone
marrow stromal cells (BMSCs)/fibroblasts, osteoblasts, and endothelial cells, in
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addition to blood vessels.25 The non-cellular compartment of the BM includes a
complex extracellular matrix (ECM), oxygen, and a liquid milieu composed of
cytokines, growth factors, and chemokines, which are produced by the cellular
compartment within the BM microenvironment. The BM ECM consists of
fibronectin (FN), laminin, proteoglycans, glycosaminoglycans, and various
collagens, which provide scaffolding for the cellular compartments. ECM
arrangement is critical for normal hematopoiesis and the tumor microenvironment
of various cancers by contributing to cell survival, proliferation, and metastasis.26,27

1.4 Plasma Cell Niche
The fundamental observation that plasma cells are sustained within the BM
for decades implies that BM provides a complement of survival factors that support
their existence. Once established within a BM niche, plasma cells can persist,
effectively becoming long-lived PCs. Numerous factors, both soluble and
insoluble, have been described to contribute to the long-lived PC niche.28,29 PCs
also require specific cell-cell interactions with BM stromal cells to persist. This
interaction induces stromal cell production of interleukin-6 (IL-6), which enhances
plasma cell survival.29,30
Unlike normal PCs which migrate throughout peripheral tissues, long-lived
PCs reside within the BM and slowly proliferate. It is thought that BM resident longlived PCs are transformed into MM cells with the ability to uncontrollably proliferate.
Myeloma cell localization within the BM milieu allows for cell-cell interactions
between tumor cells and non-tumor BM cells, which promote neoplastic cell
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growth, survival, bone disease, acquisition of drug resistance, and consequential
relapse.3,31 Additionally, research has shown that interactions between PCs and
ECM within this niche contributes to myeloma cell survival and therapeutic
resistance.22,32
Soluble and membrane-bound survival factors found in normal long-lived
PC niches, such as IL-6, have been shown to play a critical role in promoting
plasma cell activity in MM. Additional factors such as A Proliferation-Inducing
Ligand (APRIL) and myeloid cell leukemia-1 (Mcl-1) are also important in the
survival of myeloma cells.28 These essential survival factors play a role in
maintaining the growth and expansion of plasma cells within the BM.33 Several
survival ligand–receptor pairs have been discovered both in vitro and in vivo
including: FN–very late antigen 4 (VLA-4), IL-6–gp130, and APRIL–B-cell
maturation antigen (BCMA).34 Specifically, IL-6 is emphasized as a key player in
MM pathogenesis by inhibiting apoptosis in myeloma cells. IL-6 also interacts with
several factors involved in the development and progression of MM, such as
adhesion molecules, tumor suppressor genes, and oncogenes.35,36 Clinically, MM
patients have elevated serum levels of IL-6, which is associated with poor
prognosis.37 APRIL is also necessary for the survival of PCs and, when bound to
BCMA, can activate several signaling pathways that mediate cell growth and
survival.38–41 Mcl-1 is similarly critical for the survival of myeloma cells in vitro and
in vivo.42 Through its overexpression in myeloma cells, Mcl-1 contributes to
therapeutic resistance in conventional chemotherapies.43–45 Furthermore, Mcl-1 is
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highly regulated by survival signaling triggered by various cytokines and growth
factors located in the BM liquid milieu.

1.5 Treatment of Multiple Myeloma
It is known that the PC niche and surrounding BM microenvironment play
significant roles in supporting the growth, survival, progression, and therapeutic
resistance in MM, thereby representing an ideal target for anti-MM therapies. For
more than the past 15 years, new classes of nongenotoxic treatments disrupting
the interactions between myeloma cells and its niche have been introduced into
the therapeutic armamentarium for MM. This has led to substantial improvements
in the treatment of this disease. In particular, the immunomodulatory drugs
thalidomide and lenalidomide, and the first-in-its-class proteasome inhibitor
bortezomib, have formed the backbone of newer treatments that are currently used
in both up-front and relapse-refractory settings.46–48 Additionally, the more
conventional treatment option of glucocorticoids, such as dexamethasone,
remains widely used in combination therapies with immunomodulatory drugs and
proteasome inhibitors.26 Stem cell transplantation, allogeneic and autologous, is
also a treatment option for select myeloma patients. Autologous stem cell
transplantation is more common, where the patient’s own hematopoietic stems
cells are infused back into the patient’s blood after treatment with high-dose
chemotherapy or radiation.49 Despite the increasing therapeutic advancements
that prolong patient survival, MM remains an incurable malignancy.48 Nearly all
patients eventually relapse, and this high rate of relapse, which is sometimes
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refractory, suggests that more effective and sensitive treatment methods remain
imperative.

1.6 Current Approaches
Novel approaches used to treat MM focus on disruption of the myeloma cell
microenvironment, which provides numerous essential survival factors and
scaffolding that allows for the persistence of malignant PCs. Though this niche has
been defined biochemically and genetically, the 3D microstructure has not been
clearly resolved.25 Research demonstrates that normal and malignant plasma cell
niches differ in gene expression profiles, cell phenotypes, and function. Thus, the
3D arrangement of the BM ECM and survival factors are likely to differ in normal
and malignant states. Numerous hurdles are present in studying human PCs.
There is a lack of in vitro systems available to generate and maintain mature
long-lived PCs. The vast majority of in vitro research using myeloma cells have
been carried out in 2D or planar cultures; however, PC in vitro survival is short and
variable with no indication of an extended life span.50 Additionally, preclinical
studies using simplistic in vitro models have found novel anti-MM agents that have
not translated to in vivo clinical benefits. This is due to the lack of studies on 3D
BM architecture and/or tumor microenvironment, which are necessary to
adequately model the disease and limited studies have utilized 3D culture
techniques.51–55
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1.7 Rationale
The overall goal of this project is to investigate differences in the BM
microenvironment of patients being screened for MGUS and MM, while also
generating a patient specific collagen-based three-dimensional in vitro model of
the disease. This would allow for the investigation of the complex interactions
which occurs as the BM transition from premalignant to active MM. There are
biochemical and genetic changes between normal and malignant plasma cell
niches.

Therefore,

investigating

microstructural

differences

between

the

premalignant and malignant stages can provide valuable information that can be
exploited to test current therapies, as well as the development of novel treatments.
The overall hypothesis of this study is that changes in the 3D
microenvironment of premalignant and malignant plasma cells promote
oncogenesis and therapeutic resistance. The results described herein stem from
specific aims designed to examine factors influencing plasma cells in the BM
microniche of MM patients:
Specific Aim 1: To elucidate differences in the microenvironment of
premalignant and malignant plasma cells.
Specific Aim 2: To generate a 3D patient specific in vitro model of multiple
myeloma malignant transformation and resistance.
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CHAPTER 2
BONE MARROW MICROENVIRONMENT AND PLASMA CELL NICHE OF
MULTIPLE MYELOMA PATIENTS

2.1 Abstract
Multiple myeloma is a hematologic malignancy that is characterized by the
proliferation of abnormal bone marrow plasma cells and the overproduction of
immunoglobulin with evidence of end-organ damage including hypercalcemia,
anemia, renal dysfunction, and lytic bone lesions. The pathogenesis of MM is
closely related to changes in the extracellular matrix, as well as the dysregulation
of the unfolded protein response and ER stress. This study revealed significant
changes in fibronectin expression, which was associated with disease
progression. Additionally, electron micrographs of plasma cells from BM biopsies
exhibited morphological changes from the transition of monoclonal gammopathy
of undetermined significance to active multiple myeloma. Furthermore, the
presence of LC3 puncta in myeloma patients represent the presence of autophagy
within patient samples.
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2.2 Introduction
Despite the introduction of new targeted treatments, multiple myeloma
(MM) remains an incurable plasma cell (PC) neoplasm.12,25,56–58 It is the second
most common hematologic malignancy, accounting for 10% of all hematological
malignancies.49 In 2019, it is estimated that there will be 32,110 new cases of MM
with approximately 12,960 deaths.1 MM is a cytogenetically heterogenous clonal
disorder that typically evolves from an asymptomatic premalignant stage called
monoclonal gammopathy of undetermined significance (MGUS) prior to becoming
active, symptomatic MM.11,15,19

Endoplasmic Reticulum Stress, Unfolded Protein Response, and Autophagy in
Multiple Myeloma
One of the characteristics of MM is the excessive production of monoclonal
immunoglobulin, also referred to as paraprotein, by malignant PCs. This high level
of immunoglobulin production induces endoplasmic reticulum (ER) stress and
proteasomal degradation of the paraprotein is required to avoid ER stress-induced
apoptosis.59,60 ER stress occurs when there is an accumulation of unfolded and/or
misfolded protein which exceeds the rate of protein refolding or degradation. With
an exception of a small subset of patients (1-5% of MM patients), most patients
diagnosed with MM characteristically produce excessive levels of paraprotein.60,61
The continual production of paraprotein subjects myeloma cells to continual ER
stress allowing for myeloma cells to become highly dependent on the unfolded
protein response (UPR) for survival.59
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Myeloma cells exploit several molecular mechanisms to counteract the toxic
proteins including UPR pathway, the upregulated expression of heat shock protein
chaperones, and the autophagy-lysosome pathway.62–64 Increased UPR mediated
signaling can coordinate and activate autophagy to reduce ER stress.65,66
Consequently, the induction of ER stress mediates apoptosis in myeloma cells,
increasing survival. The pathogenesis of MM is closely linked to dysregulation of
the UPR in the ER.67,68 Studies have shown that key downstream chaperones,
such as grp94, in the ER that mediates the UPR is highly expressed in malignant
plasma cells in patients with MM, but not in patients with MGUS.68
Autophagy offers a potential pathway that may protect myeloma cells as it
is crucial for sustainable immunoglobulin production by plasma cells and for the
long-lived humoral immunity.63 Autophagy is a degradation process of proteins and
organelles in which double-membrane vesicles, called autophagosomes,
sequester cytosolic proteins and/or organelles. Studies suggest that autophagy
may be a critical additional process by which the malignant PCs could protect from
toxic misfolded immunoglobulins.69 Limited studies have demonstrated changes in
autophagy with the disease progression of MM.

Bone Marrow Microenvironment in Multiple Myeloma
The current treatment approach for MM includes immunomodulators,
proteasome inhibitors, glucocorticoids, and autologous hematopoietic stem cell
transplantation.9,56 Though these treatments target the BM microenvironment and
prolong the survival of MM patients, MM remains an incurable disease and nearly
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all patients eventually relapse. High rates in relapse suggest that clinically
undetectable minimal residual disease persists after treatment, and proliferation of
the remaining myeloma cells cause the ultimate relapse.27 This indicates the
importance of the BM microenvironment for malignant progression. The bone
marrow (BM) tissue is thought to contain at least four types of extracellular matrix
(ECM) proteins, including fibronectin (FN), which is expressed throughout the
BM.70 The expression and activation of adhesion molecules, such as FN, are
essential for mediating homotypic interactions among nearby myeloma cells and
the heterotypic engagement by surrounding BM stromal cells.21 This increased
expression is essential for the development of chemotherapeutic drug resistance
in MM patients.71 Therefore, the discovery of more effective and selective therapies
remains imperative. The effects of autophagy on the survival of myeloma cell and
changes in the fibronectin may provide critical insights for the treatment of the
disease.
The biochemical and genetic composition of normal and malignant plasma
cells have been studied, yet limited research is available that examines possible
3D microstructural differences and its relationship to myeloma cell survival and
therapeutic resistance.6,72–74 Thus, examining the 3D microniche of MM patient
biopsies can elucidate changes in the microniche of premalignant and malignant
plasma cells. Here, microscopy techniques were utilized to examine differences in
fibronectin and autophagy in the plasma cell niche of MM patients.
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2.3 Materials and Methods
Patient Biopsy Samples
Bone marrow core biopsies were obtained from patients undergoing
diagnosis for MGUS, low MM (10-20%), and high MM (>20%). Approval for these
studies was obtained from Greenville Health System Institutional Review Board
and all patient samples were collected after informed consent per GCP guidelines
(IRB # Pro00067642). After patient biopsy, BM cores were immediately place into
4% paraformaldehyde or 2%gluteraldehye/2% paraformaldehyde for confocal
microscopy and transmission electron microscopy, respectively.

Immunofluorescence
Bone

marrow

core

samples

fixed

in

4%

paraformaldehyde

for

immunofluorescence were extensively washed in 1X phosphate-buffered saline
(PBS) to remove excess fixative prior to staining for CD138, a plasma cell marker
(no.PA5-16918; Thermo Fisher, Waltham, MA USA), fibronectin (no. MAB19181;
Novus, Centennial, CO USA), and LC3, an autophagy marker (no. GTX632501;
GeneTex,

Irvine,

CA

USA).

Samples

were

decalcified

using

14%

ethylenediaminetetraacetic acid (EDTA) in ammonium hydroxide at room
temperature, with daily changes of the 14% EDTA solution (~2 – 4 days), prior
rinsing in PBS two times for 1 hour each. Samples were soaked in 15% sucrose in
PBS at 4ºC with constant agitation until sample sinks to bottom then immersed in
30% sucrose in PBS at 4ºC with constant agitation overnight. Samples were then
embedded in Tissue Plus O.C.T. Compound. Samples were frozen rapidly using
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dry ice and 2-methyl-butane. The frozen samples were sectioned at 10-20 µm
using the Zeiss Microm 505HN Cryostat.
Non-decalcified core biopsies were permeabilized with 0.1% Triton X100/PBS three times for 30 min each followed by a 0.3M Glycine wash for 45 min
and three rinses in PBS. Samples were then blocked in 5% bovine serum albumin
in phosphate-buffered saline (BSA/PBS) for one hour at room temperature before
being placed in 2%BSA/PBS overnight at 4°C with constant agitation. Samples
were incubated in primary antibodies [1:100] in 1%BSA/PBS for two days at 4°C.
BM cores were rinsed with 1%BSA/PBS three times for 20 min each prior to
incubating with secondary antibodies [1:100] in 1%BSA/PBS for two days at 4°C
(Alexa 488 and Alexa 546 no. A11034, no. A11003, Thermo Fisher, Waltham, MA
USA; DyLight 550 no. NB7494R Novus, Centennial, CO USA). Biopsies were
rinsed two times for 20 min each in PBS prior to being counterstained with DAPI
[1:5000] for 40 min at room temperature. Samples were then rinsed with PBS for
20 min prior to mounting with deionized water. Images were captured on the Lecia
SP8 multiphoton confocal.
Decalcified, frozen sections were permeabilized with 0.1% Triton X100/PBS, washed in 0.3M Glycine, and blocked with 2% BSA/PBS buffer as
previously stated. Sections were incubated in primary antibodies [1:100] overnight
at 4ºC then secondary antibodies [1:100] were incubated for 1 hour at 37ºC prior
to rinsing and counterstaining with DAPI [1:5000]. Sections were mounted with
DABCO and imaged using Lecia SP8 multiphoton confocal and Lecia SP8 TCS
confocal microscope.
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The percentage of area occupied by fibronectin was quantified by randomly
selecting three imaging areas within a patient BM for MGUS (n=3) and MM (n=3)
patients. The average percentage was calculated.

Transmission Electron Microscopy (TEM)
Approximately 1mm3 of the fresh core biopsy was immediately fixed in 2%
glutaraldehyde/2% paraformaldehyde under constant agitation at 4°C. Samples
were decalcified using 14% EDTA solution. Samples were rinsed three times in 1X
PBS buffer for 30 min each at room temperature. A secondary fix in an OsO4
solution (1% osmium tetroxide with 1.5% K+ Ferricyanide) was done for 30 min.
Samples were quickly rinsed with water then rinsed again with water twice for
10min each. The sample was dehydrated in an ethanol gradient of increasing
concentrations: 70% ethanol twice for ten min each, 95% ethanol twice for ten min
each, and lastly 100% ethanol twice for ten min each. Next, the sample was
changed to the intermediate solvents: 1:1 ratio of ethanol to acetonitrile for five
min, and then in 100% acetonitrile twice for ten min each. To prepare the resin,
PolyBed 812 was removed from the freezer, previously prepared. Briefly, the resin
was prepared accordingly: 51.13 g of PolyBed812, add DDSA until 78.15g, add
NMA until 100.00g. The resin solution was mixed well, including the sides, and
stored in 50mL conicals at -20 C until ready for use. The resin was warmed to
room temperature followed by the addition of 0.4mL DMP-30. The mixture was
stirred, not vortexed, thoroughly before proceeding. For resin infiltration, a 2:1 ratio
of acetonitrile to PolyBed 812 was added to the sample for 30 min followed by the
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addition of a 1:2 ratio of acetonitrile to PolyBed 812 for 30 min. Pure PolyBed 812
was added twice, the first for 30 min and the second overnight on the rotator.
Sample embedding was completed on the second day. One piece of tissue
was added in each Flat Embedding Mold before filling the mold to the top with
PolyBed 812. After the molds were labeled, they were placed into a 60ºC oven for
48 hours.
Samples were sectioned ultrathin at a thickness of 100nm, which were
subsequently stained with 2% uranyl acetate and Hanaichi lead citrate. Images
were captured with the JEOL 1400 Plus Transmission Electron Microscope.

Statistical Analysis
Statistical analysis to evaluate changes in percentage of area occupied by
fibronectin was determined by an unpaired t test. Data are reported as mean ± SD.
Differences between groups were considered significant at P < 0.05.

2.4 Results
Changes in Fibronectin Associated with Disease Progression
Frozen BM core sections were stained and imaged to determine changes
in FN expression associated with disease transition from MGUS to active MM.
Data demonstrated that MGUS patients presented with a low percentage of
fibronectin expression, based on staining intensity (Figure 2.1), and there is
minimal plasma cell involvement. As the disease progressed to active MM, patient
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cores displayed a significant increase in the percentage of fibronectin expression
associated with the increase of CD138+ cells (Figures 2.2, 2.3, 2.4).

Plasma Cell Morphology and Autophagy
Bone marrow biopsies from patients being screened for premalignant
MGUS and malignant MM were subjected to transmission electron microscopy to
demonstrate differences in plasma cell morphology as it relates to disease
progression. Plasma cells from these core biopsies were found to have eccentric
nuclei (Figures 2.5A, 2.6A, 2.6A), typical of normal PC morphology. In addition to
these normal PCs, MGUS, low MM, and high MM samples were observed to have
atypical plasma cells with extensive ER found throughout their cytoplasm (Figures
2.5B, 2.6B, 2.7B). Additionally, a third phenotype of PC was observed in MM
patients. These PCs were found to have densely packed vesicles throughout their
cytoplasm (Figures 2.6C, 2.7C), which was not seen in the premalignant core
samples. This phenotype is indicative of a cell undergoing autophagy.65
To delineate the presence of autophagy in myeloma patient samples, core
biopsies were stained with CD138 and LC3, an autophagosome marker. MGUS
and myeloma patients exhibited areas of diffuse distribution of the LC3 protein,
while other areas within the same sample presented with punctuated patterns of
LC3 (Figure 2.8).
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2.5 Discussion
Changes in the BM microenvironment and plasma cell niche contribute to
the disease progression and persistence of MM. The ECM arrangement plays a
crucial role in normal hematopoiesis and the tumor environment of various cancers
by contributing to cell survival, proliferation, and metastasis.13,27,75 The homing of
myeloma cells to the BM depends on their interaction with ECM proteins, as well
as autocrine and/or paracrine signaling mediated by chemokines and growth
factors. Collagen type I, collagen type IV, fibronectin, and laminin are critical ECM
proteins present within the BM, with collagen type I and fibronectin
predominating.34,76 Integrins mediate the binding of myeloma cells to ECM
molecules and research has shown that myeloma cells strongly adhere to
fibronectin.77 Additionally, the interactions between PCs and ECM can contribute
to myeloma cell survival and therapeutic resistance.22,32 In this study, there was a
significant increase in percentage of area occupied by fibronectin as the disease
progressed from MGUS to MM. The increase in FN expression was associated
with increases in CD138+ plasma cells. Thus, further supporting the view that FN
plays a key role in the tumor microenvironment of MM.
Multiple myeloma is a heterogenous entity with variable course and plasma
cells within the BM have a high diversity of morphology. Studies focusing on BM
smears have determined that some morphological features are more common in
clinically advanced disease, such as the number of nucleoli, the number of
myeloma cells with irregular nuclei, and larger nuclei.
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78–80

In this study, electron

micrographs displayed differences in plasma cell morphology that relates to
disease progression. Plasma cells within the samples have eccentric nuclei, which
is morphologically associated with normal PCs. Extensive rough ER was found
throughout the cytoplasm of plasma cells for all patient groups (MGUS, low MM,
high MM). This is in contrast to normal PCs that have little to no observable ER.
The abundant amount of ER may be due to increases in ER stress due to the
production of monoclonal immunoglobulin, which allows myeloma cells to become
dependent upon the UPR as a key mechanism for malignant PC survival.59
Electron micrographs from MM patients also exhibited ab increase in densely
packed vesicles, which was not present within MGUS samples. These results
warrant further investigation to determine if autophagosomes were present within
the BM cores.
The excessive production of monoclonal immunoglobulin relies on the UPR
for myeloma cell survival.

60,64

Studies have found that the UPR can trigger

autophagic activation in response to the accumulation of unfolded proteins.
Studies have also shown that autophagy may be an important additional process
by which malignant plasma cells could be protected from the toxic misfolded
paraprotein.69,81,82 Furthermore, basal autophagy levels have been found in
myeloma cells as a response to ER stress, and the activation of autophagy has
been shown to be important for myeloma cell viability.65 Results from this study
have demonstrated LC3 punctate staining within MGUS and MM patient core
samples, which is indicative of autophagosomes. Additionally, areas presented
with diffuse LC3 staining, suggesting that autophagosomes are not present
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throughout the entire BM core. These results would further support that view that
autophagy is ramped up in transformed cells, but not in normal plasma cell niches,
and that this increase is beneficial for tumor maintenance and progression.83,84

2.6 Conclusions
In this study, premalignant and malignant patient BM cores displayed
changes in fibronectin expression and plasma cell morphology. MGUS and
myeloma patients also exhibited with LC3 puncta, which is associated with
autophagy. These results elucidated changes in the BM microenvironment that
play critical roles in the survival and progression of myeloma cells, further
demonstrating the importance of the PC niche. Ultimately, these results can
provide insight into 3D microstructural differences, which may be ideal targets for
the therapeutic treatment of MM.
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Figure 2.1. Representative confocal images from two MGUS bone marrow core cryosections exhibited less than 10%
plasma cells (green) with low expression levels of fibronectin (red) staining intensity. Blue staining is DAPI. Scale Bars:
100µm.
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Figure 2.2. At low (A) and high (B) magnification, cryosectioned bone marrow cores from multiple myeloma patients display
an increase in fibronectin expressed, based on staining intensity. Staining: DAPI (blue), CD138 (green), and FN (Red).
Scale bars: 100µm and 50µm.

Figure 2.3. Non-decalcified myeloma bone marrow cores were stained for confocal
microscopy, and the resulting Z-stack (120 µm) demonstrates increased
fibronectin (red) expression that is associated with malignant, CD138+ plasma
cells (green). Blue staining is DAPI.
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Figure 2.4. There is a significant increase in the percentage of fibronectin
expression from the transition of MGUS to multiple myeloma. ** P ≤ 0.01.
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Figure 2.5. Representative electron micrograph of plasma cells from patients diagnosed with MGUS. Plasma cells (A)
present with an eccentric nucleus, while other plasma cells within the sample present with an abundant amount of
endoplasmic reticulum with minimal vesicles present (B). Scale bars: 2 µm.

Figure 2.6. Electron micrographs of plasma cells from multiple myeloma patients with 10-20% monoclonal plasma cells.
Differences can be seen between these plasma cells including increases in ER (B) and vesiculation (C). Scale bars: 2 µm.
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Figure 2.7. Electron micrographs from myeloma patients with <20% plasma cells present with normal eccentric nuclei (A),
increases in ER (B), and increases in vesiculation (C). Scale bars: 2 µm.
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Figure 2.8. Non-decalcified BM cores for MGUS (A) and MM (B) patients, in addition to cryosections (C) from myeloma
patients. Biopsies presented with both diffuse distribution and punctate pattern of LC3 protein (red). Blue staining is DAPI
and green staining is CD138.

CHAPTER 3
PATIENT DERIVED THREE-DIMENSIONAL COLLAGEN MODELS OF MULTIPLE
MYELOMA PROGRESSION

3.1 Abstract
Niches within the tumor bone marrow microenvironment create a unique
milieu for multiple myeloma cells due to interactions which confer survival
advantages and drug resistance. Defining the sequelae of myeloma cell
interactions within these microenvironments on an individualized basis may
provide the rational for personalized therapies; however, there are limited 3D
models capable of mirroring patient plasma cell niches. To mimic the myeloma cell
niche, here we describe a 3D ex-vivo model in which primary patient bone marrow
cells are cultured in a collagen hydrogel matrix. In this 3D hydrogel model,
prolonged survival of malignant plasma cells was observed after five days of
culture.

3.2 Introduction
Multiple myeloma (MM) is the second most common hematological
malignancy that is characterized by aggregation and proliferation of malignant
plasma cells (PCs) within the bone marrow (BM). These cancerous PCs are
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influenced by their tumor microniche in addition to genetic abnormalities.85
Particularly, fibroblasts/stromal cells, endothelial cells, immune cells, and the
extracellular matrix (ECM) have profound effects on MM cells. Collagen type I,
collagen type IV, fibronectin, and laminin are critical ECM proteins present within
the BM, with collagen type I and fibronectin predominating.34,76 The interactions
between myeloma cells and the supporting BM microenvironment plays critical
roles in pathogenesis, mediating resistance to cell death, sustained proliferation,
cell homing and invasion, and immunosuppression, thereby promoting MM
progression.86 Therefore, characterizing the efficacy of novel agents should not
only assess the impact on myeloma cells, but also define effects on the tumor
microenvironment.87,88
Several impediments remain in the study of human plasma cells. There is a
lack of in vitro systems that are able to culture and maintain long-lived plasma
cells. In traditional 2D or planar cultures, PC survival is relatively short, typically
around three days. Previous studies have demonstrated that in order to maintain
their phenotype in culture, PCs require components of the tumor microenvironment
such as essential survival factors and/or BM stromal cells.28,33 These reports have
also indicated that interleukin 6 (IL-6) supports the generation of plasma cells in
vitro.
In MM patients, IL-6 has been identified as a key factor in pathogenesis by
inhibiting apoptosis in myeloma cells. IL-6 also interacts with several factors
involved in the development and progression of MM, such as adhesion molecules,
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tumor suppressor genes, and oncogenes.35,36 Clinically, MM patients have
elevated serum levels of IL-6, which are associated with poor prognosis.37
Numerous preclinical studies have demonstrated novel anti-MM agents,
which have not translated to patient clinical benefits. One of the many challenges
in treating myeloma is its genomic and phenotypic heterogeneity. This may be due
to limitations in drug testing without the appropriate tumor environment and/or the
lack of 3D BM architecture seen in patients. An emphasis on using 3D in vitro
models, instead of conventional planar methods, to create an experimental system
recapitulating the specialized characteristics of the MM BM has been
demonstrated previously using: ECM molecules such as collagen and/or
fibronectin; specialized scaffolds including gelatin sponges or silk; microfluidic
tissues, as well as bioreactor-based cultures.51,53,89–92
Previously, we have utilized type I collagen for numerous in vivo and in vitro
models in various fields including cardiovascular tissues, valve development, the
foreign body response, and others.93–99 Since collagen type I is abundant within
the plasma cell niche of myeloma cells, it seems logical to use collagen as a
scaffold when attempting to generate 3D models of the BM microenvironment.
From prior research, it is apparent that additional comprehensive, patient-specific
studies are needed to thoroughly mimic and investigate the malignant myeloma
niche.
Here, we introduce an in vitro 3D model to mimic the myeloma niche
composed of patient-derived BM and myeloma cells embedded in a hydrogel 3D
system. This hydrogel model allows for the study of cellular and extracellular
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components in the myeloma microenvironment including hematopoietic, immune,
and tumor cells. In this study, we investigated the prolonged survival of PCs in a
collagen hydrogel that is capable of recapitulating the complex microenvironment,
in a patient-specific manner. Results from multiple analytical approaches indicated
that PCs in this 3D hydrogel system maintained their pathological phenotype for at
least five days of culture, thus suggesting that patient-derived BM aspirates can
be used to model key features of long-lived plasma cell malignant progression
within this in vitro model.

3.3 Material and Methods
Patient Aspirates and Cell Isolation
Primary BM cells from patients with premalignant condition or MM were
studied including monoclonal gammopathy of undetermined significance (MGUS),
low MM (15-20% PCs), and high MM (60-70% PCs). Approval for these studies
was obtained from Greenville Health System Institutional Review Board (IRB #
Pro00067642). All patient samples were collected after informed consent per GCP
guidelines. After BM aspiration, fresh BM leukocytes were obtained by ammonium
chloride based-lysis of red blood cells. Isolated BM cells were washed in 0.5%
bovine serum albumin in phosphate-buffered saline (BSA/PBS) twice and then
complete RMPI1640 media supplemented with 10% fetal bovine serum, 100U/mL
penicillin, 100µg/mL streptomycin, and 250µg/mL amphotericin B.
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Generation of 3D Constructs
Type I collagen (no. C857; Elastin Products Co. Owensville, MO USA) was
diluted in 0.01M acetic acid to a concentration of 10mg/mL. Isolated patient cells
(1.0 ´ 106 cells/mL) were gently incorporated into the collagen at a ratio of 1:2 (cell
suspension: collagen) prior to 100 µL of the mixture being carefully added to a 96well plate. The well plate was incubated for 20 min at 37°C in 5% CO2 to allow for
gelation and polymerization. After initial incubation, complete RMPI1640 media +/IL-6 (10ng/mL) was added and changed two times over a period of 40 min to
equilibrate the growth environment to physiological pH. Fresh media was added
and constructs were gently dissociated from the walls of the well plates and
cultured up to 5 days at 37°C in 5% CO2.

Enzyme-Linked Immunosorbent Array (ELISA)
Isolated patient cells were seeded within type I collagen as previously
described and supernatants were collected after one and five days of culture.
Particulates were removed by centrifugation for 10 min at 1,500 rpm prior to being
aliquoted and stored at -80°C until analysis. For analysis, supernatants were
diluted at a ratio of 1:4 and the Human IgG ELISA (no. ab195215; Abcam
Cambridge, MA USA) was used according to manufacturer’s instructions.

Immunofluorescence
The three-dimensional collagen constructs were collected after one and
five days of culture and placed into 4% paraformaldehyde. The constructs were
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permeabilized with 0.1% Triton X-100/PBS three times for 15 min each followed
by a 0.3M Glycine wash for 30 min. Collagen gels were rinsed with PBS and
blocked in 2% BSA/PBS for 1 hour at room temperature. Samples were incubated
in primary antibodies [1:100] in 1%BSA/PBS overnight at 4°C. Collagen gels were
stained with CD138 (no.PA5-16918; Thermo Fisher, Waltham, MA USA). Then,
constructs were rinsed with 1%BSA/PBS two times for 15 min each and 1X PBS
for 15 min prior to incubating with appropriate secondary antibodies [1:100] in
1%BSA/PBS for 1 hour at 37°C (Alexa 488 no. A11034; Thermo Fisher, Waltham,
MA USA). Collagen gels were rinsed three times in PBS for 15 min each prior to
being counterstained with DAPI [1:5000] for 20 min at room temperature. After a
final rinse in PBS, constructs were mounted with deionized water and imaged at
25X on the Lecia SP8 multiphoton confocal microscope.
The percentage of plasma cells per patient construct was quantified by
dividing the number CD138+ cells by the total number of nuclei. Four random fields
were imaged per constructs and the average percentage was calculated.

Statistical Analysis
Statistical analysis to evaluate changes in IgG levels and in the percentage
of CD138+ cells were determined by 2-way analysis of variance and Sidak’s
multiple comparisons test. Data are reported as mean ± SD. Differences between
groups were considered significant at P < 0.05.
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3.4 Results
To mimic the neoplastic BM microniche of myeloma cells, patient BM
leukocytes were cultured in a hydrogel-based 3D model. In the 3D model, PCs at
premalignant and malignant stages of MM remained viable five days after culture
(Figure 3.1).

Characterization of Patient Constructs
Monoclonal Gammopathy of Undetermined Significance
Bone marrow aspirates were collected and processed for patients
undergoing screening for premalignant MGUS. To verify the viability of MGUS
leukocytes within the collagen constructs, supernatants were analyzed for
changes in IgG concentration after five days of culture. Overall, MGUS 3D collagen
constructs exhibited a lower concentration of IgG production by day 5 despite the
addition of IL-6. There was an increase in IgG concentration from day 1 to day 5
when patient #1030 and #1032 constructs were cultured without IL-6 (Figure 3.2).
A significant decrease in IgG was observed by day 5 when patient 1030 collagen
gels were cultured in the presence of IL-6. Additionally, there was a decrease in
IgG concentration for patient #1032 when cultured with IL-6, though this difference
was not significant (Figure 3.2). Collagen constructs then were stained with
CD138, a plasma cell marker, to determine changes in the percentage of PCs
within the gels over five days. There was an increase in CD138+ cells within patient
#1030 and #1032 constructs by day five, regardless of treatment with IL-6 (Figure
3.1 A, B, Figure 3.3)
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Multiple Myeloma, 15-20% Plasma Cells
Isolated leukocytes from MMpatients that present with 15-20% monoclonal
plasma cells were embedded within the collagen hydrogel. Patient #1027 showed
significant increases in IgG concentration between day 1 and day 5 when cultured
with or without IL-6 (Figure 3.4). Additionally, there was an increase in the
percentage of CD138+ cells by day 5 when constructs were cultured with or without
IL-6, though this difference was not significant (Figure 3.5, Figure 3.1 C, D). Patient
#1033 exhibited a significant increase in IgG concentration between day 1 and day
5 when cultured without IL-6. When constructs were cultured in the presence of IL6, IgG concentration in patient #1033 constructs remained constant over five days
(Figure 3.4). Increases in the percentage of CD138+ PCs were seen from day 1 to
day 5 when constructs were cultured with or without IL-6, though these increases
were not significant (Figure 3.5).

Multiple Myeloma, 60-70% Plasma Cells
Isolated cells from myeloma patients with 60-70% plasma cells were also
cultured within the collagen gel. There was a significant decrease seen in IgG
concentration for patient #1022 and #1034 constructs by day 5 when cultured
without IL-6; however, when cultured in the present of IL-6, there was a significant
increase in IgG by day 5 for both patients (Figure 3.6). There were decreases in
the percentage of CD138+ PCs from day 1 to day 5 when constructs were cultured
without IL-6 for both patients (Figure 3.7). When cultured with IL-6, there was a
significant increase in CD138+ cells for patient #1022 from day 1 to day 5.
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Additionally, patient #1034 constructs also exhibited an increase in CD138+ cells
when cultured with IL-6, though this increase was not significant (Figure 3.7, Figure
3.1 E, F).

3.5 Discussion
Multiple myeloma remains an incurable disease due to challenges in
treatment due to genomic and phenotypic heterogeneity.6,16 This may also be due
to limitations in therapeutic testing without the supporting tumor microenvironment
and/or the lack of BM architecture that is seen within patients. Numerous 2D,
planar models have demonstrated novel MM agents that have not translated to in
vivo benefits. Research has shown that the tumor microniche is critical for the
maintenance and progression for myeloma cells. This study utilized type I collagen
to create 3D patient specific constructs. Results indicate that isolated BM
leukocytes from premalignant and malignant myeloma patients maintained their
pathological phenotype for at least five days of culture within the collagen, which
is well beyond typical short-lived plasma cell cultures. While future studies
involving further manipulation and analysis is required, this 3D hydrogel-based
model presented provides an innovative method for gaining insight in MM disease
progression from premalignant MGUS to active MM.
In this study, the expression level of IgG was utilized as a functional assay
to determine plasma cell viability after five days of culture. Furthermore, constructs
were stained and imaged to determine the percentage of CD138+ plasma cells
during the culture period. First, patient constructs cultured without IL-6 were
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analyzed. Expression levels of IgG increased after five days in MGUS constructs
despite patient to patient variation. An increase was also seen in the percentage
of CD138+ cells within the MGUS gels. These results suggest that we have
maintained the pathological PC phenotype of MGUS patients for at least five days
of culture. MM constructs containing 15-20% PCs displayed a significant increase
in IgG concentration. Furthermore, this increase was also seen in the percentage
of CD138+ cells, though not significant. Further supporting that long-lived plasma
cells can be maintained within this 3D collagen model, as components of their
specific tumor microenvironment provided the critical essential factors necessary
for their survival. Interestingly, in myeloma constructs with 60-70% PCs there was
a significant decrease in IgG production and decreases in the percentage of
plasma cells. These results suggest there was potentially a limited number of
necessary supporting microenvironment factors within the collagen cultures, which
is expected due to the high percentage of monoclonal cells in the BM cellularity.
These high myeloma constructs indicated the importance of the in vivo tumor
microniche for the in vitro study of long-lived plasma cells because without these
essential components or additional factors introduced, plasma cells are unable to
survive for five days in vitro. 21,28,33
Interleukin-6 is a key essential survival factor in MM that has been shown
to play critical roles in maintaining the growth and expansion of plasma cells within
the BM.33,35,36,100–102 IL-6 is key in MM progression and pathogenesis by inhibiting
PC apoptosis, while interacting with other factors involved in the development of
MM. Additionally, IL-6 plays a key role in supporting the maintenance of long-lived
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plasma cells in vitro.23,103,104 In this study, IL-6 played an important role in
maintaining the long-lived plasma cells. When MGUS constructs were cultured in
the presence of IL-6, paradoxically there was a decrease in IgG concentration, but
there was an increase in the percentage of plasma cells within the constructs after
five days of culture. Though IgG concentration decreased by day 5 in MGUS
constructs, the increase of CD138+ cells suggests that IL-6 can support myeloma
cell maintenance in cultures. Since these MGUS patients presented with lower
serum IgG levels compared to the myeloma patients, perhaps IgG was not an
appropriate validation assay for these patients as MGUS and myeloma patients
can also produce high levels of IgA or light chain only immunoglobulins.105,106
In comparison to MGUS constructs, MM constructs, 15-20% and 60-70%,
exhibited significant increases in IgG concentration after five days of culture.
Additionally, there were increases in the percentage of CD138+ cells within the
patient constructs after five days. Overall, findings in the myeloma constructs
supports previous studies which demonstrated that IL-6 is an important factor in
culturing long-lived plasma cells.107–109
The patient derived 3D collagen model described in the study is capable of
maintaining myeloma cell viability for at least five days of culture. This creates a
critical experimental window in which PC/MM cell biology can be explored. The
broader applications of this work include detailed analysis of the long-lived plasma
cell survival microniche as it transitions from its primary role in humoral function to
a pathogenic role as in MM. Furthermore, results from this project will lead to the
development of high-fidelity human models of normal and pathological myeloma
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BMs. Though this preliminary study needs to be further validated in prospective
trials, the results do suggest that our 3D culture system may be utilized to predict
the clinical utility of novel myeloma therapies.

3.6 Conclusions
In this study, an in vitro 3D model to mimic the myeloma cell niche was
introduced using patient derived BM and myeloma cells which were embedded in
a 3D hydrogel-based system. Importantly, the 3D patient cultures maintained the
pathological phenotype of plasma cells for at least five days of culture. Therefore,
providing a patient specific model to explore the growth of MM clones associated
with therapeutic resistance and the transition of long-lived PCs from humoral
function to malignancy. Ultimately, the 3D collagen constructs may asses tumor
sensitivity to conventional and novel anti-MM therapies, and thereby inform single
agent or combination individualized therapy.
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Figure 3.1. Isolated patient BM leukocytes were cultured in a 3D collagen-based
model of multiple myeloma. Blue shows nuclei and green shows CD138, a plasma
cell marker. Scale Bar: 100µm.
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Figure 3.2. IgG concentration in MGUS collagen constructs. MGUS patients exhibit
an increase in IgG expression levels five days after culture, however the addition
of IL-6 decreased IgG concentration in patient gels. * P < 0.05.
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Figure 3.3.The percentage of CD138+ plasma cells increased from day 1 to day 5
when isolated MGUS patient cells were cultured in the collagen gel, with or without
IL-6.
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Figure 3.4. MM patient (15-20% plasma cells) cell constructs cultured without IL-6
demonstrated a significant increase in IgG expression levels after five days of
culture. The addition of IL-6 to the gels resulted in a significant increase in IgG
concentration for patient #1027, while patient #1033’s levels remained constant
during the culture period. * P < 0.05
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Figure 3.5. BM cells isolated from multiple myeloma patients with 15-20%
monoclonal plasma cells exhibited an overall increase in CD138+ cells from day 1
to day 5, with or without the addition of IL-6.

46

Figure 3.6. MM (60-70% clonal plasma cells) constructs demonstrate significant
decreases in IgG concentration when not cultured in the presence of IL-6. Culturing
the constructs with IL-6 resulted in a significant increase in IgG expression from
day 1 to day 5. * P < 0.05.
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Figure 3.7.MM (60-70% clonal plasma cells) constructs demonstrate decreases in
the percentage of CD138+ cells when not cultured in the presence of IL-6. With
the addition of IL-6 to the culture, the percentage of plasma cells increased by day
5. * P < 0.5.
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CHAPTER 4
CONCLUSIONS

4.1 Summary
Multiple myeloma (MM) remains an incurable disease due to the high clonal
heterogeneity of myeloma cells and its clinical repercussions. Furthermore,
heterogeneity is found in regard to disease onset, disease progression, therapeutic
resistance, and subsequent patient relapse. This project investigated differences
in the BM microenvironment of MGUS and MM cells, while also generating a
patient specific collagen-based three-dimensional in vitro model of the disease
which allows for investigation of the complex interactions in the plasma cell niche.
Results from this study have demonstrated that increases in extracellular
matrix, specifically fibronectin expression, are related to disease transition from
MGUS to MM. Furthermore, morphological changes in plasma cells were also
exhibited. Electron micrographs displayed increases in ER and densely packed
vesicles associated with myeloma patients, which was not seen in premalignant
patients. Additionally, autophagosomes were present in both MGUS and MM
patients, as denoted by LC3 staining. These results demonstrate the need to
further define the three-dimensional BM microenvironment and plasma cell niche
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as it can provide further insight into therapeutic treatments of this incurable
disease.
This project also introduced a patient-specific 3D in vitro model capable of
mimicking the myeloma cell niche by embedding BM derived cells in a hydrogelbased system. This 3D model was capable of maintaining the pathological
phenotype of plasma cells for at least five days of culture. By providing a patient
specific model, this study will help to explore the growth of MM clones associated
with therapeutic resistance and the transition of long-lived PCs from humoral
function to malignancy. These constructs could asses tumor sensitivity to
conventional and novel anti-MM therapies, and thereby inform single agent or
combination individualized therapy. Validation of this model will provide a test bed
for other long-lived PC applications such as using these cells for the production of
human monoclonal antibodies in vitro. Moreover, if successful, the results of this
project will lead to the development of high-fidelity human models of normal and
pathological BMs.

4.2 Future Directions
While this study has identified expression changes of fibronectin, the
investigation of other ECM proteins such as collagen I, collagen IV, and laminin
would provide even greater insight into the BM microenvironment as it relates to
disease progression. Three-dimensional mapping of the malignant BM and plasma
cell niche can provide critical information to the spatial distribution and the
localization and colocalization of key myeloma markers, which can provide novel
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targets for the treatment of MM. Additionally, autophagy is important in MM disease
progression. As normal and malignant PCs varies within each patient, identification
of which phenotype of plasma cells presents with autophagosomes could provide
valuable insight.
An emphasis on utilizing 3D in vitro models, instead of conventional 2D
planar methods, to create an experimental system recapitulating the specialized
characteristics of the MM BM has been previously demonstrated. However,
additional models of comprehensive patient specific studies are needed to
thoroughly mimic and investigate the malignant myeloma niche. Though we have
created a patient-specific model of MM, further validation of this model is needed
to determine the difference between plasma cell survival and proliferation, as
normal long-lived PCs exhibit survival with minimal proliferation. Furthermore,
qPCR experiments examining essential survival factors between MGUS and MM
patient constructs will help to define the 3D patient models. The ultimate goal for
these 3D constructs is to create a high-fidelity test bed for current and novel MM
therapeutic agents. Using this culture system, therapeutics can be tested in
patient-specific manner. This potential bench to beside approach could help
clinicians to determine if single or combination treatments may be best for their
patients, increasing the survival rate of MM patients and potentially curing the
disease.
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APPENDIX A1
THERAPEUTIC ENGINEERED HYDROGEL COATINGS ATTENUATE THE
FOREIGN BODY RESPONSE IN SUBMUSCULAR IMPLANTS

1
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Coatings Attenuate the Foreign Body Response in Submuscular Implants. Annals
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A.1 Abstract
Background: Biomedical devices are implanted into mammalian soft tissues to
improve, monitor, or restore form or function. The utility of these implants is limited
by the subsequent foreign body response (FBR), beginning with inflammation and
terminating in a collagen envelope around the device, known as the capsule. This
capsule then can contract and distort the shape of the device or limit its
effectiveness in interacting with the surrounding host tissues. In the current study,
we investigated the effect of therapeutic collagen-coated silicone discs in a rat
model of the FBR.

Methods: A 3-dimensional printed mold was used to fabricate collagen-coated
silicone discs incorporating 3 therapeutic agents: colchicine, a function-blocking
antibody against interleukin 8 (IL-8) receptor B, and a powerful anti-inflammatory
steroid, dexamethasone. Discs were implanted submuscularly into a well
characterized rat model of the FBR and evaluated for inflammatory response,
fibrotic development, and cytokine release.

Results: Coated silicone discs exhibited reduced collagen deposition and little to
no foreign body giant cells at the host-silicone interface when compared with the
silicone-only group. Therapeutic hydrogels demonstrate a significant decrease in
cellular infiltration into the coatings over the 2-week time point in contrast to
therapeutic-free hydrogel coatings. Cytokine analysis revealed significant
differences between therapeutic-free and therapeutic-containing coatings when
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compared with silicone-only controls. Levels of IL-1β, IL-6, monocyte chemotactic
protein 1, and macrophage inflammatory protein 3α were affected 48 hours after
implantation, while differences in IL-18, growth- regulated oncogene/keratinocyte
chemoattractant, and macrophage inflammatory protein 3α were observed 1 week
after implantation.

Conclusions: By utilizing the host's innate immune response, our engineered
hydrogel coatings delivered therapeutic moieties directly to the implant
microenvironment, thus delaying the FBR up to 2 weeks.

Key Words: drug elution, foreign body reaction, hydrogel coatings, implant
capsule, implant fibrosis.

A.2 Introduction
Biomedical devices are designed to improve or restore form and/or function
through interactions with native tissue. The utility of these devices is limited by the
foreign body response (FBR). Initially, there is a peri-implant inflammation that is
eventually encapsulated in a dense connective tissue layer composed primarily of
type I collagen. The FBR is implicated in implant malfunction and failure by
inhibiting the device from responding to the local microenvironment or deforming
the shape of the implant. The FBR is a modified wound healing response that has
been well characterized and reviewed elsewhere. Briefly, cellular debris and
platelet aggregation on the surface of the implant trigger an initial inflammatory

75

reaction, recruiting neutrophils and macrophages to the implant surface via
intercellular signaling.110–112 Activated macrophages at the implant surface
undergo fusion to form multinucleated giant cells.113–115 These foreign body giant
cells are present at the tissue-implant interface and are unique to the FBR.116
Cytokines produced by neutrophils and macrophages signal fibroblast migration
onto the surface where they begin deposition of collagenous extracellular matrix
around the implant, effectively walling it off from host tissue.115 Fibroblasts
frequently differentiate into myofibroblasts, which mediate capsule contraction,
further distorting the implant.110,111
Research regarding peri-implant fibrosis has focused on topographical
changes to the implant, systemic and local administration of drugs, and coating
implants in biomaterials.110 Thus far, techniques aimed to prevent fibrotic capsule
formation have temporarily delayed the FBR. Physical modifications to the implant
include the investigation of smooth versus textured implants,117 changes in implant
thickness, and changes in implant composition. However, these alterations have
had minimal effects on ultimate capsule formation.1 Systemic administration of
drugs shown to inhibit inflammation and wound healing has not influenced capsule
formation or contraction.118–120 Similarly, the administration of drugs that affect
cellular responses occurring during the FBR is ineffective or too toxic at efficacious
levels. Therefore, we and others have used therapeutic agents and biomaterials
to loosely coat implants to improve the local microenvironment and resulting
inflammation and fibrosis.121–123 Although a temporary delay of fibrosis has been
seen, no single method has completely eliminated capsule formation, suggesting

76

that a multifactorial approach, with a variety of different inflammatory inhibiting
chemical moieties and physical properties, offers the greatest opportunity to
provide an improved host microenvironment.
Implanted

devices

create

a

procoagulatory,

proadhesive,

and

proinflammatory microenvironment in host soft tissues. Consequently, there is little
opportunity to intervene in the early stages of the innate immune response. For
this reason, we have chosen to target the next steps of the FBR, focusing on cell
recruitment, proliferation, and differentiation at the implant site and the beginning
of pathological remodeling proteases, including those that degrade extracellular
matrix molecules. We elected to coat biomedical implants with a hydrogel coating
composed of type I collagen, which would allow host collagenases to degrade the
implant coating, thereby releasing the therapeutic agents incorporated within the
hydrogel.
Here, we report the fabrication of implants coated with a degradable,
therapeutic biomaterial to control host responses, with the goal of improving
implant function and the local microenvironment. Numerous therapeutics can be
incorporated into our hydrogel coating including small molecules, antibodies, and
steroids. A well-characterized rat model of the FBR was used to submuscularly
implant silicone discs coated in the therapeutic hydrogel containing 3 agents.123
First, colchicine, clinically used to treat gout, has been shown to inhibit microtubule
formation while reducing the migration and proliferation of inflammatory cells.124,125
Next, an antibody against interleukin 8 receptor B (anti–IL-8), which has been
previously reported to limit neutrophil activation and recruitment.126,127 Lastly,
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dexamethasone, a powerful corticosteroid, is clinically used to limit inflammation
by modulation of the steroid response transcriptional network, thus preventing the
release of cytokines that cause inflammation.128–131 Dexamethasone interferes
with collagen formation further by preventing excessive scar tissue formation. In
this investigation, we used these 3 moieties, both alone and in combination, to
elucidate their effect on the early inflammatory response.

A.3 Materials and Methods
Hydrogel Fabrication
Bovine type I collagen was isolated using methods previously described in
Yost et al.96 Briefly, isolated bovine dermis was acid solubilized and pepsin
digested to an average concentration of 3.12% (dry weight/wet weight), which was
sterilized with 1200 rad γ-irradiation prior to fabrication. Therapeutic agents were
added to the collagen at final concentrations of colchicine at 40 μg/mL (Fisher
Scientific, Pittsburgh, Pa), anti–IL-8 at 833 μg/mL (R&D Systems, Minneapolis,
Minn), and dexamethasone at 350 μg/mL (Sigma, St Louis, Mo). Silicone-only and
therapeutic-free–coated controls were also used in these experiments.
A 3-dimensional polylactic acid mold was used to fabricate collagen-coated
silicone discs (Figure. A.1). The therapeutic or therapeutic-free collagen mixture
was syringed into the 3-dimensional printed mold, and a sterile 8-mm silicone disc
was placed into the center, creating a 1-mm hydrogel coating around the silicone,
as depicted in Figures A.1 B and C. Hydrogels were polymerized with 10X HEPES
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buffer at pH 7.8 for 1 hour. Polymerized hydrogel discs were then exposed to 107μJ
of UV crosslinking, per side, prior to implantation.

Experimental Animals
Sprague-Dawley rats were maintained at the Department of Laboratory
Animal Resources, University of South Carolina. The number of animals used
within this study was kept to a minimum, and all possible efforts were made to
reduce suffering in compliance with the protocols established by the Institutional
Animal Care and Use Committee of the University of South Carolina. Our
experimental protocol was approved by the Institutional Animal Care and Use
Committee (AUP #2322).
For histological analysis, silicone-only, collagen-only, colchicine + anti–IL8, and dexamethasone + anti–IL-8 coatings were fabricated and placed into a
pocket created beneath the aponeurosis of the trapezius muscles, with 1 disc
being placed in each animal. Discs and the surrounding tissue were harvested at
48 hours, 1 week, and 2 weeks after implantation. For cytokine analysis, treatment
groups included silicone-only controls, collagen-only, anti–IL-8, dexamethasone,
and dexamethasone + anti–IL-8 coatings. These discs were also placed in the
submuscular pocket and were collected 48 hours and 1 week after implantation.

Histological Assessment of Cellular Invasion
Tissue samples collected for histology were fixed, paraffin embedded,
sectioned, and processed for light microscopy. Masson trichrome stain was used
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to identify cell invasion, collagen remodeling, collagen deposition, and the
presence of foreign body giant cells. Additional sections stained with hematoxylineosin were used to investigate inflammatory cell invasion via blinded examiners.
Morphometric analysis of the remodeling process that occurs in the coatings and
surrounding tissue was quantified via the National Institutes of Health ImageJ by
determining cellular density in 3 different zones of the surrounding tissue and
hydrogel coating. Zones designated for analysis include host tissue-hydrogel
interface (THI), hydrogel (H), and silicone-hydrogel interface (SHI).

Cytokine Processing
A 5-mm3 section from the harvested implants and surrounding tissue was
frozen at −80°C. Samples were thawed, and cell lysis was carried out according to
the Bio-Plex Cell Lysis Kit protocol (Bio-Rad Laboratories, Hercules, Calif). Briefly,
tissue samples were washed, and lysing solution was added. Tissues were
homogenized prior to being frozen at −80°C. Thawed samples were sonicated and
centrifuged, and supernatants were collected. Lysates were diluted to a final
concentration of 800 μg/mL.
Sample lysates were analyzed according to the Bio-Plex Rat Cytokine
Group I (Bio-Rad Laboratories) protocol to determine differences in inflammatory
cytokine levels between silicone-only and therapeutic and nontherapeutic
hydrogels.
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Statistical Analysis
Statistical significance to evaluate cellular infiltration into the hydrogel was
determined by 2-way analysis of variance and Tukey multiple-comparisons test.
Cytokine analysis was determined by 1-way analysis of variance and Bonferroni
multiple-comparisons test with α values of 0.05. Differences between groups were
considered significant with P < 0.05.

A.4 Results
Characterization of Polymerized Hydrogels
In order to characterize the microarchitecture of our hydrogel coatings,
scanning electron microscopy was carried out on therapeutic-free hydrogels,
without a silicone disc. As seen in Figure A.2, the collagen solution polymerizes
into microfibrils that are less than 1 μm in diameter. Higher magnification
demonstrates that these fibrils form an anisotropic network of collagen, which is
capable of incorporating a wide range of therapeutic molecules, while being
biocompatible (Figure. A.2C).

Silicone-Only Implants
To demonstrate the progression of the FBR in our model system, uncoated
silicone discs were placed under the aponeurosis of the trapezius muscle. The size
and submuscular placement of the silicone disc were to model the FBR that occurs
in the commonly performed sub-pectoral breast implant procedure. Figure A.3
shows stained Masson trichrome at 1 and 2 weeks after implantation. Images
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exhibit infiltration of inflammatory cells to the site of the implant and layers of
fibrous connective tissues around the implant surface. In addition, 2-week images
show numerous multinucleated foreign body giant cells lining the silicone disc at
the host-implant interface (red arrow, Figure. A.3B).

Therapeutic-Free and Therapeutic Hydrogel Coatings
To determine the effect of therapeutic combinations in our model systems,
therapeutic-free and therapeutic hydrogel coatings were submuscularly implanted.
Implants and the surrounding tissues were then collected 48 hours, 1 week, and 2
weeks after implantation for histological analysis. Therapeutic-free coatings 48
hours after implantation displayed inflammatory cell infiltration, with most cells
located at the host THI, and limited collagen remodeling (Figure. A.4A). Less
cellular infiltration was observed in hydrogel coatings containing a combination of
colchicine + anti–IL-8 and dexamethasone + anti–IL-8 (Figures. A.4B, C). In
addition, fewer cells are located at this host-implant interface when compared with
therapeutic-free hydrogels. By 1 week, collagen-only coatings demonstrate
increased cell invasion into the hydrogel coating, with cells being distributed
throughout the collagen as opposed to being primarily located at the THI (Figure.
A.5A). Remodeling of the hydrogel coatings has also begun as robust collagen
staining (blue) is observed at the silicone interface. Colchicine + anti–IL-8 and
dexamethasone + anti–IL-8 have limited cellular invasion, with cells clustering at
the THI (Figures. A.5B, C). Minimal collagen remodeling was observed in
therapeutic-containing coatings, and little to no collagen was evident. Two weeks
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after implantation, therapeutic-free hydrogels exhibited the advanced stages of the
FBR including massive cellular infiltration throughout the coating and increased
collagen remodeling, with collagen deposition at the silicone interface (Figure.
A.6A). Colchicine + anti–IL-8 coatings show a slight increase in collagen
remodeling and cellular infiltration into the hydrogel; however, fewer cells are
present when compared with collagen-only controls (Figure. A.6B). While some
collagen remodeling has occurred in dexamethasone + anti–IL-8 hydrogels,
cellular infiltration remains low when compared with other coatings (Figure. A.6C).

Morphometric Analysis of Cellular Invasion
Sections were stained with hematoxylin-eosin, imaged, and analyzed to
determine cellular density in 3 regions of the hydrogel coatings. Figure A.7 depicts
the zones identified for analysis including THI, H, and SHI. Therapeutic-free
coatings, 48 hours after implantation, show most cells localized at the THI, with
some cells located in the H and SHI. Both combinations (colchicine + anti–IL-8 and
dexamethasone + anti–IL-8) of therapeutic hydrogels revealed a significant
decrease in inflammatory cell infiltration at the THI when compared with
therapeutic-free controls. In addition, colchicine + anti–IL-8 coatings exhibit a
significant reduction in cells present at the SHI. By week 1, controls display an
increased number of cells found at the THI. Therapeutic-containing hydrogels
significantly decreased cellular density at all 3 zones when compared with
collagen-only implants. Additional analysis demonstrated significant differences at
the 2-week time point within the THI and SHI zones for both treatments;
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furthermore, the hydrogel zone was also significant for the dexamethasone + anti–
IL-8 coating (Figure. A.8).

Inflammatory Cytokine Analysis
Lysates from the hydrogel disc and surrounding tissues were harvested to
determine levels of cytokine expression, when compared with silicone-only
controls, 48 hours and 1 week after implantation. Interleukin 1β and IL-6 were
elevated in control lysates, 48 hours after implantation, whereas therapeutic-free
and therapeutic-containing hydrogels expressed significantly lower levels (Figure.
A.9). In addition, macrophage inflammatory protein 3α (MIP-3α) was decreased in
all therapeutic-containing coatings, and monocyte chemotactic protein 1 (Figures.
A.9, A.10) levels were decreased in anti–IL-8 and dexamethasone collagen
hydrogels. By 1 week, expression levels of IL-18 were decreased in anti–IL-8
hydrogels when compared with silicone-only controls (Figure. 2.11). Growthregulated oncogene/keratinocyte chemoattractant (GRO/KC) levels significantly
increased in all therapeutic-containing coatings, and MIP-3α was elevated in anti–
IL-8 coatings (Figure. A.11). Cytokine analysis also revealed that IL-1α, IL-10,
interferon γ, and tumor necrosis factor α expression levels were not significantly
affected by the collagen hydrogel coatings, with or without therapeutic moieties.

A.5 Discussion
The foreign body reaction is an irreversible process that occurs around
biomedical implants, often providing detrimental consequences to the form and
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function of the implant. Despite temporary delays of fibrosis, no single technique
has eliminated implant encapsulation; hence, a multifactorial approach is needed
to improve the host microenvironment.110,112 A number of methodologies have
been developed prior to this investigation; however, few have used the host's
innate response to deliver therapeutic agents to the implant site.118,119 While future
studies involving further manipulation and analysis of the effects of the
therapeutics are required, our model system presented provides an innovative
method for gaining insight into implant fibrosis.
In our model, early and late visualization of the FBR has been studied; thus,
we can predict the outcome, for up to 2 months, by examining the results at 2
weeks.121 The rat FBR model system was validated by implanting silicone-only
discs. This study found that uncoated silicone discs underwent classic progression
of the FBR, which is a common clinical observation in sub-pectoral implant
procedures. This is marked by cellular invasion, collagen deposition, and the
formation of foreign body giant cells at the implant surface. The microarchitecture
of our collagen coatings exhibited polymerized microfibrils in an anisotropic
arrangement,

mimicking

irregular

connective

tissue.

The

hydrogel

is

biocompatible; however, the host's innate responses result in enzymatic activity
that degrades the collagen, allowing for the release of therapeutic agents that are
localized at the implant microenvironment. Therapeutic combinations (colchicine +
anti–IL-8 and dexamethasone + anti–IL-8) delayed the FBR 2 weeks after
implantation, when com- pared with collagen-only implants, with decreased
cellular infiltration and collagen remodeling.
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During the early progression of the FBR, macrophages are recruited to the
implant surface via intercellular signaling. Interleukin 1β and IL-6 are
proinflammatory cytokines that are produced and secreted by activated
macrophages.115 Expression levels for both IL-1β and IL-6 were significantly
decreased in collagen-coated when compared with silicone-only controls.
Furthermore, levels of cytokines known to recruit monocytes/macrophages during
the fibrotic response, monocyte chemotactic protein 1 and MIP-3α, were also
decreased, specifically in therapeutic coatings.132 At 48 hours after implantation,
these results suggest that fewer macrophages were recruited to the silicone
implant site, thus indicating that the therapeutic moieties used delayed the FBR.
By 1 week, decreased levels of IL-18 were exhibited in anti– IL-8 coatings,
whereas levels of MIP-3α were significantly elevated. Growth-regulated
oncogene/keratinocyte chemoattractant, a murine homolog to IL-8, is secreted by
adherent macrophages and foreign body giant cells in vitro, which recruits
neutrophils to the site of implantation.132,133 The GRO/KC concentrations were
significantly higher in therapeutic-containing collagen implants than in the control
group. This may be due to surface adherent cells contributing to the production of
GRO/KC.134
Our therapeutic moieties delayed the FBR response 2 weeks prior to
coatings exhibiting the progression of the response, suggesting the eventuality of
a complete reaction. The cytokine analysis of the implants may indicate that the
therapeutic moieties were no longer efficacious in delaying the FBR, and the
progression of the reaction continued beyond the 2-week time interval. The
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moieties could have been absorbed by host tissues or may have undergone
hydrolysis by host enzymes, thereby inhibiting their efficacy over the 2-week
period. Dexamethasone is a powerful corticoid steroid that should have attenuated
the FBR for an extended period, as previous studies have indicated.130,131
Unfortunately, these hydrogels exhibited minimal cellular infiltration into the
collagen, although they presented with limited collagen remodeling and little to no
foreign body giant cells. The bioactivity of dexamethasone may have been
compromised during the fabrication process, specifically UV crosslinking, which
could have diminished its efficacy over the 2-week time point. Thus, further
experimentation is necessary to effect of crosslinking on the activity of our
moieties.

A.6 Conclusions
Using a unique fabrication approach that allows for the incorporation of
various therapeutic agents into a hydrogel coating implanted into a wellcharacterized rat model, we have created an implant that delays and alters the
FBR 2 weeks after implantation. The limitation of the model is the eventual
dissipation or degradation of the drugs incorporated into the collagen. Future
investigations involve utilizing all 3 therapeutic moieties, and others, in an attempt
to elicit a sustained and regenerative response to the implantation of biomaterials.
The complex cytokine signaling during the FBR has been extensively studied;
however, the ability to drive this response away from a fibrotic scar and toward a
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regenerative process has met with limited clinical success. Our hydrogel coating
has the capability of incorporating small molecules and viable cells.
Finally, our model allows for the incorporation of viable cells, including stem
cells, into the collagen matrix, which may provide a future direction for our research
by influencing the behavior and activity of the inflammatory cells. Our fabrication
process offers a substantial approach with extensive potential to contribute to the
field of research for implant fibrosis.
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Figure A.1. A schematic of the 3-dimensional polylactic acid mold (A) used to fabricate implants with uniform dimensions,
creating an 8-mm silicone disc with a 1-mm collagen coating (B, C).
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Figure A.2.Therapeutic-free hydrogels, without a silicone disc, demonstrate the microarchitecture of polymerized collagen,
with microfibrils less than 1 μm in diameter. Increasing magnification shows an anisotropic fibril network, resembling
collagen fibrils found in irregular dense connective tissue, confirming biocompatibility (original magnification ´100, ´2700,
´5000).
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Figure A.3. Uncoated silicone discs implanted submuscularly displays the progression of the FBR within the rat model
system. One week after implantation (A), layers of fibrous connective tissue have been deposited around the silicone
implant, indicated by the blue stain. By 2 weeks (B), macrophages have undergone fusion to form multinucleated foreign
body giant cells that line the implant surface (red arrow). Masson trichrome stain.
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Figure A.4. Therapeutic-free collagen coatings (A), 48 hours after implantation, present with inflammatory cell infiltration
into the hydrogel, and most cells are located at the THI. Less cell infiltration can be seen in colchicine + anti–IL-8 (B) and
dexamethasone + anti–IL-8 (C) coatings.
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Figure A.5. One-week collagen coatings (A) demonstrate increased cellular invasion into the hydrogel, with cells being
distributed throughout the collagen, and collagen remolding has begun. Colchicine + anti–IL-8 (B) and dexamethasone +
anti–IL-8(C) therapeutic coatings have limited cell infiltration, and most cells are clustered at the THI. Minimal collagen
remolding can be seen within these coatings.
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Figure A.6. Two weeks after implantation, collagen hydrogels (A) have massive cell infiltration within the coatings, and
inflammatory cells are present at the SHI. New collagen deposition has begun at the silicone interface. Colchicine + anti–
IL-8 (B) hydrogels exhibit a slight increase in cellular invasion; however, fewer cells are present at the SHI. Dexamethasone
+ anti–IL-8 (C) coatings have limited cellular infiltration when compared with other collagen coatings.

Figure A.7. Hematoxylin-eosin images were divided into 3 equal zones for morphometric analysis: THI, where host tissue
encounters the implanted collagen coating, hydrogel interface (H) is consistent of collagen coating only, and SHI, where
collagen coating meets the silicone implants.
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Figure A.8. Morphometric analysis of cellular infiltration into the collagen coating
48 hours, 1 week, and 2 weeks after implantation. When compared with collagenonly controls, colchicine + anti–IL-8 and dexamethasone + anti–IL-8 coatings
present with significantly fewer cells within the THI 48 hours after implantation. By
1 week, hydrogel-only implants demonstrate an increase in cellular density within
the coating. Therapeutic-containing hydrogels presented with a decrease in
cellular density within the THI, H, and SHI interfaces. By 2 weeks, colchicine +
anti–IL-8 and dexamethasone + anti–IL-8 collagen coatings continue to exhibit
decreased cellular infiltration and the THI and SHI interfaces, when compared with
collagen only coatings. In addition, dexamethasone + anti–IL-8 discs show a
significant decrease at the hydrogel interface. Differences were considered
significant with P < 0.05.
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Figure A.9. Proinflammatory cytokines, IL-1β and IL-6, that are produced and
secreted by activated macrophages exhibited decreased expression levels in all
hydrogel coatings when compared with silicone-only controls, 48 hours after
implantation. Expression levels of MIP-3α were significantly lower in therapeuticcontaining coatings.
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Figure A.10. Monocyte chemotactic protein 1, responsible for the recruitment of
monocytes and macrophages during the fibrotic response, expression levels were
significantly reduced in hydrogel coatings containing anti–IL-8 and
dexamethasone coatings at 48 hours.
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Figure A.11. By 1 week, decreased expression levels of IL-8 and increased levels
of MIP-3α were exhibited in anti–IL-8 coatings when compared with silicone-only
controls. Growth-regulated oncogene/keratinocyte chemoattractant demonstrated
increased levels in therapeutic-containing coatings.
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